10 results
8-K
EX-99.1
BBIO
BridgeBio Pharma Inc
4 Aug 22
BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update
4:43pm
Disorders (PAS) Congress. Results showed that BBP-671 was detected in healthy volunteer plasma and cerebrospinal fluid, suggesting that BBP-671
8-K
EX-99.1
BBIO
BridgeBio Pharma Inc
24 Feb 22
BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
7:38am
-671 – PanK activator for pantothenate kinase-associated neurodegeneration (PKAN) and organic acidemias: BridgeBio has completed the healthy volunteer
8-K
EX-99.1
BBIO
BridgeBio Pharma Inc
14 May 21
BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update
5:30pm
patient in Phase 2 trial of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i in February 2021.
Dosed first healthy volunteer in Phase 1 trial of BBP-671
S-1
EX-10.9
oajygh6jvpm ym
24 May 19
IPO registration
4:46pm
S-1
EX-10.17
gh7x28gt
24 May 19
IPO registration
4:46pm
DRS/A
EX-10.17
nl5garv1 w4pjkph4
16 May 19
Draft registration statement (amended)
12:00am
DRS/A
EX-10.9
du83n
16 Apr 19
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next